Haemonetics (HAE) Cost of Revenue (2009 - 2026)

Haemonetics' Cost of Revenue history runs 18 years deep, the most recent figure standing at $148.1 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 7.7% year-over-year to $148.1 million in Q1 2026; TTM through Mar 2026 was $546.4 million, a 10.69% decrease from a year earlier, with the FY2026 full-year figure at $546.4 million, down 10.69% from the prior year.
• Cost of Revenue improved to $148.1 million in Q1 2026 per HAE's latest filing, from $136.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $167.4 million in Q1 2024 and bottomed at $119.2 million in Q3 2022.
• The 5-year median for Cost of Revenue is $145.3 million (2022), against an average of $143.3 million.
• Across the five-year window, Cost of Revenue climbed 20.95% in 2022 and dropped 19.91% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $146.6 million in 2022, then grew by 8.04% to $158.4 million in 2023, then retreated by 2.14% to $155.0 million in 2024, then decreased by 11.88% to $136.6 million in 2025, then rose by 8.46% to $148.1 million in 2026.
• Per Business Quant, the three latest HAE Cost of Revenue figures stand at $148.1 million (Q1 2026), $136.6 million (Q4 2025), and $132.6 million (Q3 2025).